Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Centerspace's acquisition by Independence Realty Trust, Fulcrum Therapeutics' acquisition by Slate Medicines, Weave Communications' acquisition by Francisco Partners, and Personalis' acquisition by Tempus AI.

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and ensure fair value for shareholders. The investigations involve Personalis (acquired by Tempus AI for $16.25/share), Werewolf Therapeutics (acquired by Ambros Therapeutics), Beazer Homes (acquired by Dream Finders Homes for $33.50/share), and MarketAxess Holdings (acquired by Intercontinental Exchange for $167/share).

Tempus AI stock surged 39.5% this week following positive Phase 3 trial results from Merck and Moderna for a jointly developed mRNA cancer vaccine combined with Keytruda immunotherapy. The gains were driven by Tempus's pending acquisition of Personalis, which developed the genomic tumor-profiling technology central to the vaccine's development. Despite the rally, Tempus remains down roughly 10% over the past year.

Law firm Wohl & Fruchter is investigating whether the Personalis board acted in shareholders' best interests regarding the proposed $16.25 per share sale to Tempus AI. Since the announcement on July 20, 2026, Personalis shares have fallen approximately 14% due to the deal's partial stock consideration and Tempus share price decline. Shareholders have expressed disappointment with the transaction.

Law firm Julie & Holleman is investigating Personalis' proposed acquisition by Tempus AI for $16.25 per share, raising concerns about fair value and potential conflicts of interest given Tempus' existing significant equity stake and strategic partnership with Personalis since 2023.

Tempus AI CEO Eric Lefkofsky sold 250,000 shares worth $10.5 million on July 28, 2026, reducing his stake by 4% through a pre-scheduled trading plan established in March. Despite the sale, Lefkofsky retains approximately 6.5 million shares. The article suggests this represents routine portfolio management rather than a loss of confidence, noting the company's strong Q2 2026 performance with 20% YoY revenue growth and 31% oncology volume growth, plus a strategic $1.5 billion acquisition of Personalis.

Halper Sadeh LLC, an investor rights law firm, is investigating several companies for potential securities law violations and breaches of fiduciary duties related to proposed acquisitions. The investigations focus on whether shareholders are receiving fair consideration and whether insider benefits may be prioritized over ordinary shareholder interests. The firm is seeking increased consideration, additional disclosures, and other relief on behalf of affected shareholders.

Julie & Holleman LLP is investigating Personalis Inc.'s proposed acquisition by Tempus AI for $16.25 per share. The law firm is concerned about potential conflicts of interest given Tempus' existing significant equity stake and strategic relationship with Personalis since 2023, and whether shareholders are receiving fair value for their shares.

Personalis reported Q2 2025 financial results with revenue falling 24% year-over-year to $17.2 million, missing estimates. Despite financial challenges, the company saw a 59% increase in clinical test volumes for its NeXT Personal platform, with promising cancer detection research.

AI is transforming healthcare with projected market growth exceeding $110 billion by 2030, enabling advanced diagnostic tools, early disease detection, and more efficient medical research across multiple sectors.

The global gene panel market is projected to reach $11.75 billion by 2031, growing at a CAGR of 19.30% during the forecast period. The market growth is driven by advancements in genomic research, rising prevalence of genetic disorders, and growing awareness of genetic testing.

Tempus AI, a niche AI company, has increased its stake in Personalis, a biotech firm specializing in cancer diagnostics. The move has led to a significant surge in Tempus AI's stock price, outperforming the broader market.